Apnimed files for IPO as FDA reviews its sleep apnea drug

Kevin Lind, Apnimed CEO July 10, 2026 05:23 PM EDT DealsIPOs Ap­n­imed files for IPO as FDA re­views its sleep ap­nea drug Kyle LaHucik Biotech Correspondent Ap­n­imed is fi­nal­ly go­ing for­ward with an IPO at­tempt af­ter years of flirt­ing with the mile­stone. The Cam­bridge, MA-based biotech re­vealed its Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER